Farnoosh Shariati
Cardiovascular Disease · Orlando, FLNPI 1710541529
Payments from drug & device makers
Across 154 payments — averaging $30.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$607
- Abbott$598
- Amgen$559
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$509
- Novartis$377
- Pfizer$352
- plus $2K from 15 others
What the payments were for
- Food & beverage$4,767100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $607 |
| Abbott | 14 | $598 |
| Amgen | 16 | $559 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $509 |
| Novartis | 15 | $377 |
| Pfizer | 16 | $352 |
| Johnson & Johnson | 11 | $266 |
| Kestra Medical Technology Services, Inc. | 9 | $230 |
| Boston Scientific | 4 | $215 |
| AstraZeneca | 11 | $197 |
| Abiomed | 5 | $185 |
| Alnylam Pharmaceuticals Inc. | 6 | $173 |
| Boehringer Ingelheim | 6 | $152 |
| E.r. Squibb & Sons, L.L.C. | 5 | $99 |
| Livanova USA, Inc. | 3 | $94 |
| Biosense Webster, Inc. | 1 | $38 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| Lexicon Pharmaceuticals, Inc. | 1 | $28 |
| Inari Medical, Inc. | 1 | $24 |
| Merck | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,767 in reported general payments places this provider in the 55th percentile of 1,740 cardiovascular disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 26 | $27,469 |
| JardianceEmpagliflozin | 19 | $22,784 |
| EliquisApixaban | 16 | $17,251 |
| Repatha SureclickEvolocumab | 12 | $10,263 |
| Metoprolol Succinate | 21 | $315 |
| Atorvastatin Calcium | 35 | $245 |
| Carvedilol | 22 | $214 |
| Rosuvastatin Calcium | 13 | $160 |
| Valsartan | 12 | $139 |
| Amlodipine Besylate | 12 | $132 |
| Ezetimibe | 17 | $126 |
| ClopidogrelClopidogrel Bisulfate | 25 | $107 |
| Hydrochlorothiazide | 22 | $106 |
| Nifedipine ErNifedipine | 11 | $106 |
| Doxycycline Hyclate | 11 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $377 | $27,46926 claims |
| Boehringer IngelheimJardiance | $152 | $22,78419 claims |
| PfizerEliquis | $352 | $17,25116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Orlando
- Rohit BhathejaOrlando$896K
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.